Abcuro Announces $66 Million Series D Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis

Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study Series READ MORE The post Abcuro Announces $66 Million Series D Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis appeared first on Abcuro .